Kyowa Kirin Co Ltd - Company Profile
Powered by
All the data and insights you need on Kyowa Kirin Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Kyowa Kirin Co Ltd Strategy Report
- Understand Kyowa Kirin Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, immunology and allergy, oncology, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
Kyowa Kirin Co Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pharmaceuticals: | Pasetocin |
Erythropoietic Stimulating Agent | Adriacin |
Agent for Hypertension and Angina | Fortimicin |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Plans/Strategy | In February, the company announced its plans to invest US$200 million to establish a pharmaceutical manufacturing facility in Sanford, North Carolina, the US. |
2024 | Acquisitions/Mergers/Takeovers | In January, the company acquired Orchard Therapeutics. |
2024 | Contracts/Agreements | In January, the company entered into a partnership with LG Chem to market Nephoxil in Korea. |
Competitor Comparison
Key Parameters | Kyowa Kirin Co Ltd | Takeda Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Eisai Co Ltd | Taisho Pharmaceutical Holdings Co Ltd |
---|---|---|---|---|---|
Headquarters | Japan | Japan | Japan | Japan | Japan |
City | Chiyoda-Ku | Chuo-Ku | Chuo-Ku | Bunkyo-Ku | Toshima-Ku |
State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
No. of Employees | 5,974 | 49,095 | 7,604 | 11,076 | 8,784 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Masashi Miyamoto, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2018 | - |
Takeyoshi Yamashita, Ph.D. | Director; Senior Managing Executive Officer | Executive Board | 2022 | - |
Motohiko Kawaguchi | Chief Financial Officer; Head - Global Finance | Senior Management | - | - |
Yasuo Fujii | Chief Strategy Officer | Senior Management | 2023 | - |
Wataru Murata | Chief People Officer; Global Human Resources Head | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer